The efficacy of HA330-II column hemoadsorption in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis combined with liver failure: a case report

BACKGROUND Hemophagocytic lymphohistiocytosis (HLH) is a severe and potentially deadly condition associated with extensive inflammation and immune activation. Cytokine adsorption may serve as a supportive treatment that can stabilize organ function in affected patients by reducing their circulating cytokines levels. To date, no descriptions of clinical experiences associated with the use of HA330-II column hemoadsorption for the treatment of HLH children have been published. CASE SUMMARY We describe a 11-year-old children with Epstein-Barr virus (EBV)-associated HLH combined with liver failure. She underwent HA330-II column hemoadsorption and chemotherapy, and developed a decreased inflammatory cytokines including interleukin (IL)-6, IL-8, IL-10, and interferon (IFN)-γ. The patient’ condition and laboratory parameters gradually improved. CONCLUSION Hemoadsorption may play an important role in eliminating cytokines storm in children with Hemophagocytic lymphohistiocytosis combined with liver failure and consequent multiple organ failure. Keywords: hemoadsorption; HA330-II column; Hemophagocytic lymphohistiocytosis; Pediatric; Liver failure; Case report